Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis

Minoru Nakamura

doi:10.1055/s-0034-1383732

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2014; 34(03): 334-340
DOI: 10.1055/s-0034-1383732

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis

Minoru Nakamura

¹Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Clinical Research Center in National Hospital Organization (NHO), Nagasaki Medical Center, Omura, Nagasaki, Japan

› Institutsangaben

Abstract

Antimitochondrial, anti-gp210, anti-sp100, and anticentromere antibodies are specifically detected in primary biliary cirrhosis (PBC). In clinical practice, they are useful for the diagnosis of PBC or for evaluating disease severity, clinical phenotype, and long-term outcome. In the typical or classical form of PBC which shows slow progressive loss of small bile ducts with a parallel increase in liver fibrosis, anti-gp210 antibodies are a strong risk factor for progression to jaundice and hepatic failure, whereas the presence of anticentromere antibodies is a risk factor for progression to cirrhosis and portal hypertension. Of note, the autoimmune repertoire, which is established during the early stage of the disease process, can influence the clinical phenotype and the long-term prognosis of PBC. Because the natural course of PBC is being altered by treatment with ursodeoxycholic acid, the clinical significance of these PBC-specific autoantibodies awaits re-evaluation in various ethnicities.

Keywords

antimitochondrial antibodies - antinuclear antibodies - anti-gp210 antibodies - anticentromere antibodies - primary biliary cirrhosis

Volltext

Referenzen

References
1 Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353 (12) 1261-1273
2 Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52 (5) 745-758
3 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50 (1) 291-308
4 Beuers U, Boberg KM, Chapman RW , et al; European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2) 237-267
5 Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010; 55 (8) 2144-2161
6 Hu CJ, Zhang F-C, Li Y-Z, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us?. World J Gastroenterol 2010; 16 (29) 3616-3629
7 Leung PSC, Coppel RL, Ansari A, Munoz S, Gershwin ME. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17 (1) 61-69
8 Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25 (3) 298-310
9 Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 2013; 37 (6) 572-585
10 Nakamura M, Komori A, Ito M , et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis. Hepatol Res 2007; 37 (Suppl. 03) S412-S419
11 Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 2011; 50 (1) 1-10
12 Hirschfield GM, Gershwin ME. Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J 2011; 13 (1) 55-59
13 Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138 (10) 3525-3531
14 Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988; 1 (8594) 1067-1070
15 Fussey SPM, Guest JR, James OFW, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci U S A 1988; 85 (22) 8654-8658
16 Gershwin ME, Rowley M, Davis PA, Leung P, Coppel R, Mackay IR. Molecular biology of the 2-oxo-acid dehydrogenase complexes and anti-mitochondrial antibodies. Prog Liver Dis 1992; 10: 47-61
17 Moteki S, Leung PSC, Coppel RL , et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 1996; 24 (1) 97-103
18 Oertelt S, Rieger R, Selmi C , et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007; 45 (3) 659-665
19 Dähnrich C, Pares A, Caballeria L , et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009; 55 (5) 978-985
20 Liu H, Norman GL, Shums Z , et al. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010; 35 (4) 436-442
21 Bizzaro N, Covini G, Rosina F , et al. Overcoming a “probable” diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature. Clin Rev Allergy Immunol 2012; 42 (3) 288-297
22 Saito H, Takahashi A, Abe K , et al. Autoantibodies by line immunoassay in patients with primary biliary cirrhosis. Fukushima J Med Sci 2012; 58 (2) 107-116
23 Lazaridis KN, Juran BD, Boe GM , et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46 (3) 785-792
24 Mitchison HC, Bassendine MF, Hendrick A , et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?. Hepatology 1986; 6 (6) 1279-1284
25 Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996; 348 (9039) 1399-1402
26 Mattalia A, Quaranta S, Leung PS , et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998; 27 (3) 656-661
27 Benson GD, Kikuchi K, Miyakawa H, Tanaka A, Watnik MR, Gershwin ME. Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clin Dev Immunol 2004; 11 (2) 129-133
28 Van Norstrand MD, Malinchoc M, Lindor KD , et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997; 25 (1) 6-11
29 Nakanuma Y, Harada K, Kaji K , et al. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. Liver 1997; 17 (6) 281-287
30 Invernizzi P, Crosignani A, Battezzati PM , et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25 (5) 1090-1095
31 Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int 2008; 28 (2) 233-239
32 Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis 2008; 12 (2) 323-331 , viii–ix
33 Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol 2006; 16 (1) 30-34
34 Jin Q, Moritoki Y, Lleo A , et al. Comparative analysis of portal cell infiltrates in . antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012; 55 (5) 1495-1506
35 Poupon RE, Balkau B, Eschwège E, Poupon R. UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324 (22) 1548-1554
36 Worman HJ, Courvalin J-C. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2003; 2 (4) 211-217
37 Granito A, Muratori P, Quarneti C, Pappas G, Cicola R, Muratori L. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn 2012; 12 (1) 65-74
38 Worman HJ, Courvalin J-C. Autoantibodies against nuclear envelope proteins in liver disease. Hepatology 1991; 14 (6) 1269-1279
39 Courvalin J-C, Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997; 17 (1) 79-90
40 Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23 (5) 1020-1024
41 Nakamura M, Shimizu-Yoshida Y, Takii Y , et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42 (3) 386-392
42 Itoh S, Ichida T, Yoshida T , et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998; 13 (3) 257-265
43 Invernizzi P, Podda M, Battezzati PM , et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001; 34 (3) 366-372
44 Muratori P, Muratori L, Ferrari R , et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (2) 431-437
45 Miyachi K, Hankins RW, Matsushima H , et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003; 20 (3) 247-254
46 Yang W-H, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2004; 2 (12) 1116-1122
47 Wesierska-Gadek J, Penner E, Battezzati PM , et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43 (5) 1135-1144
48 Nakamura M, Kondo H, Mori T , et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45 (1) 118-127
49 Nakamura M, Yasunami M, Kondo H , et al; PBC Study Group in NHOSLJ*. Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC. Hepatol Res 2010; 40 (5) 494-504
50 Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130 (3) 715-720
51 Kumagi T, Guindi M, Fischer SE , et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105 (10) 2186-2194
52 Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55 (6) 1361-1367
53 Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med 2008; 8 (1) 9-15
54 Nakamura M, Kondo H, Tanaka A , et al. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis. Hepatol Res 2014; . In press
55 Nakamura M, Nishida N, Kawashima M , et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 2012; 91 (4) 721-728
56 Invernizzi P, Ransom M, Raychaudhuri S , et al; Italian PBC Genetics Study Group. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes Immun 2012; 13 (6) 461-468
57 Kar SP, Seldin MF, Chen W , et al; Italian PBC Genetics Study Group. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun 2013; 14 (3) 179-186
58 Szostecki C, Guldner HH, Will H. Autoantibodies against “nuclear dots” in primary biliary cirrhosis. Semin Liver Dis 1997; 17 (1) 71-78
59 Züchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26 (5) 1123-1130
60 Rigopoulou EI, Davies ET, Pares A , et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54 (4) 528-532
61 Bogdanos DP, Baum H, Butler P , et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig Liver Dis 2003; 35 (11) 801-805
62 Mytilinaiou MG, Meyer W, Scheper T , et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis. Clin Chim Acta 2012; 413 (15-16) 1211-1216
63 Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360 (19) 1989-2003
64 Reveille JD, Solomon DH. American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49 (3) 399-412
65 Parveen S, Morshed SA, Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995; 10 (4) 438-445
66 Rigamonti C, Shand LM, Feudjo M , et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55 (3) 388-394
67 Shi T-Y, Zhang L-N, Chen H , et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol 2013; 19 (7) 1111-1118
68 Granito A, Yang W-H, Muratori L , et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010; 105 (1) 125-131
69 Wesierska-Gadek J, Klima A, Ranftler C , et al. Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. J Cell Biochem 2008; 104 (1) 27-37